#JustTheData is a new series by Cancer Communicator delivering an easy-to-read snapshot of recently presented clinical trial data.
The phase 3 CONTACT-02 randomized 507 patients with mCRPC (adenocarcinoma) to cabozantinib plus atezolizumab (n=248) or a second novel hormonal therapy (NHT; n=252).
Noted Baseline Characteristics in the ITT population:
Median age: 71 years
Noted poor prognostic features (cabo/atezo vs second NHT)
Bone metastases: 81% vs 77%
Visceral metastases: 39% vs 41%
Liver metastases: 23% vs 24%
PFS per BICR in the ITT population (median follow-up: 14.3 months):
OS per BICR:
Response:
Treatment-emergent AEs at rates of 15% or more and higher with cabozantinib/atezolizumab included diarrhea, decreased appetite and weight, fatigue, nausea, asthenia, AST and ALT increase, anemia, hypothyroidism, hypertension, and constipation.
There were questions raised during the discussion and Q&A regarding whether second NHT is an appropriate control arm and whether how patient censoring impacted PFS significance.
Please see the study design and ASCO GU presentation for full details.
References:
Agarwal N, et al. ASCO GU. 2024. Abstract 18.
Comentarios